… Peter Doshi has raised some concerns regarding SARS-CoV-2 vaccine effectiveness and
adverse effects.[1] To shed more light on some of these issues, I try to interpret the evolution of …

It seemed a truth universally acknowledged that the human population had no pre-existing
immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging …

Introduction In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a
priority list, endorsed by the World Health Organization, of potential adverse events relevant …

There has been considerable controversy over the past year, particularly in Europe, over
whether the World Health Organization (WHO) changed its definition of pandemic influenza in …

Background Neuraminidase inhibitors (NIs) are stockpiled and recommended by public
health agencies for treating and preventing seasonal and pandemic influenza. They are used …

Objective To describe the potential benefits and harms of oseltamivir by reviewing all clinical
study reports (or similar document when no clinical study report exists) of randomised …

Objectives To update a 2005 Cochrane review that assessed the effects of neuraminidase
inhibitors in preventing or ameliorating the symptoms of influenza, the transmission of …

Background Neuraminidase inhibitors (NI) are recommended for use against influenza and
its complications in inter‐pandemic years and during pandemics. Objectives To assess the …

Unpublished and misreported studies make it difficult to determine the true value of a treatment.
Peter Doshi and colleagues call for sponsors and investigators of abandoned studies to …

… Copyright: © 2012 Doshi et al. This is an open-access article distributed under the terms
of the Creative Commons Attribution License, which permits unrestricted use, distribution …